Literature DB >> 21629257

AAV9: over the fence and into the woods . . .

John R Forsayeth1, Krystof S Bankiewicz.   

Abstract

Mesh：

Year:  2011        PMID： 21629257      PMCID： PMC3129793          DOI： 10.1038/mt.2011.95

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  18 in total

1.  Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.

Authors:  M A Kay; C S Manno; M V Ragni; P J Larson; L B Couto; A McClelland; B Glader; A J Chew; S J Tai; R W Herzog; V Arruda; F Johnson; C Scallan; E Skarsgard; A W Flake; K A High
Journal:  Nat Genet       Date:  2000-03       Impact factor: 38.330

2.  Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates.

Authors:  Steven J Gray; Valerie Matagne; Lavanya Bachaboina; Swati Yadav; Sergio R Ojeda; R Jude Samulski
Journal:  Mol Ther       Date:  2011-04-12       Impact factor: 11.454

3.  Immune responses to adenovirus and adeno-associated virus in humans.

Authors:  N Chirmule; K Propert; S Magosin; Y Qian; R Qian; J Wilson
Journal:  Gene Ther       Date:  1999-09       Impact factor: 5.250

4.  Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice.

Authors:  Ciaran D Scallan; Haiyan Jiang; Tongyao Liu; Susannah Patarroyo-White; Jurg M Sommer; Shangzhen Zhou; Linda B Couto; Glenn F Pierce
Journal:  Blood       Date:  2005-10-25       Impact factor: 22.113

5.  Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery.

Authors:  Haiyan Fu; Julianne Dirosario; Smruti Killedar; Kimberly Zaraspe; Douglas M McCarty
Journal:  Mol Ther       Date:  2011-03-08       Impact factor: 11.454

6.  Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors.

Authors:  Christine L Halbert; A Dusty Miller; Sharon McNamara; Julia Emerson; Ronald L Gibson; Bonnie Ramsey; Moira L Aitken
Journal:  Hum Gene Ther       Date:  2006-04       Impact factor: 5.695

Review 7.  Current status of gene therapy trials for Parkinson's disease.

Authors:  Massimo Fiandaca; John Forsayeth; Krystof Bankiewicz
Journal:  Exp Neurol       Date:  2007-08-24       Impact factor: 5.330

8.  Development of efficient viral vectors selective for vascular smooth muscle cells.

Authors:  Lorraine M Work; Stuart A Nicklin; Nick J R Brain; Kate L Dishart; Dan J Von Seggern; Michael Hallek; Hildegard Büning; Andrew H Baker
Journal:  Mol Ther       Date:  2004-02       Impact factor: 11.454

9.  Clades of Adeno-associated viruses are widely disseminated in human tissues.

Authors:  Guangping Gao; Luk H Vandenberghe; Mauricio R Alvira; You Lu; Roberto Calcedo; Xiangyang Zhou; James M Wilson
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

Review 10.  Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer.

Authors:  Inchan Kwon; David V Schaffer
Journal:  Pharm Res       Date:  2007-09-01       Impact factor: 4.200
View more
  10 in total

Review 1.  Gene therapy: light is finally in the tunnel.

Authors:  Huibi Cao; Robert S Molday; Jim Hu
Journal:  Protein Cell       Date:  2012-01-10       Impact factor: 14.870

Review 2.  Gene therapy for misfolding protein diseases of the central nervous system.

Authors:  Waldy San Sebastian; Lluis Samaranch; Adrian P Kells; John Forsayeth; Krystof S Bankiewicz
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

3.  Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates.

Authors:  Lluis Samaranch; Ernesto A Salegio; Waldy San Sebastian; Adrian P Kells; Kevin D Foust; John R Bringas; Clementine Lamarre; John Forsayeth; Brian K Kaspar; Krystof S Bankiewicz
Journal:  Hum Gene Ther       Date:  2012-03-28       Impact factor: 5.695

4.  Targeted delivery of self-complementary adeno-associated virus serotype 9 to the brain, using magnetic resonance imaging-guided focused ultrasound.

Authors:  Emmanuel Thévenot; Jessica F Jordão; Meaghan A O'Reilly; Kelly Markham; Ying-Qi Weng; Kevin D Foust; Brian K Kaspar; Kullervo Hynynen; Isabelle Aubert
Journal:  Hum Gene Ther       Date:  2012-10-15       Impact factor: 5.695

5.  Retrograde gene delivery to hypoglossal motoneurons using adeno-associated virus serotype 9.

Authors:  Mai K ElMallah; Darin J Falk; Michael A Lane; Thomas J Conlon; Kun-Ze Lee; Nadeem I Shafi; Paul J Reier; Barry J Byrne; David D Fuller
Journal:  Hum Gene Ther Methods       Date:  2012-04       Impact factor: 2.396

6.  Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses.

Authors:  Agnieszka Ciesielska; Piotr Hadaczek; Gabriele Mittermeyer; Shangzhen Zhou; J Fraser Wright; Krystof S Bankiewicz; John Forsayeth
Journal:  Mol Ther       Date:  2012-08-28       Impact factor: 11.454

7.  Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders.

Authors:  Adam K Bevan; Sandra Duque; Kevin D Foust; Pablo R Morales; Lyndsey Braun; Leah Schmelzer; Curtis M Chan; Mary McCrate; Louis G Chicoine; Brian D Coley; Paul N Porensky; Stephen J Kolb; Jerry R Mendell; Arthur H M Burghes; Brian K Kaspar
Journal:  Mol Ther       Date:  2011-08-02       Impact factor: 11.454

Review 8.  Adeno-Associated Viral Vectors as Versatile Tools for Parkinson's Research, Both for Disease Modeling Purposes and for Therapeutic Uses.

Authors:  Ana Fajardo-Serrano; Alberto J Rico; Elvira Roda; Adriana Honrubia; Sandra Arrieta; Goiaz Ariznabarreta; Julia Chocarro; Elena Lorenzo-Ramos; Alvaro Pejenaute; Alfonso Vázquez; José Luis Lanciego
Journal:  Int J Mol Sci       Date:  2021-06-15       Impact factor: 5.923

9.  Fiber-modified adenovirus for central nervous system Parkinson's disease gene therapy.

Authors:  Travis B Lewis; Joel N Glasgow; Ashley S Harms; David G Standaert; David T Curiel
Journal:  Viruses       Date:  2014-08-21       Impact factor: 5.048

Review 10.  Gene-based therapy of Parkinson's Disease: Translation from animal model to human clinical trial employing convection enhanced delivery.

Authors:  Gurwattan S Miranpuri; Lauren Kumbier; Angelica Hinchman; Dominic Schomberg; Anyi Wang; Hope Marshall; Ken Kubota; Chris Ross; Karl Sillay
Journal:  Ann Neurosci       Date:  2012-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.